KARYOPHARM THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
KARYOPHARM THERAPEUTICS INC. - More news...
KARYOPHARM THERAPEUTICS INC. - More news...
- Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Karyopharm Announces 1-for-15 Reverse Stock Split
- Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress
- Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025
- Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives
- Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer
- Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications
- Karyopharm Therapeutics Provides Endometrial Cancer Program Update
- Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference
- Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer
- Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress
- Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024
- Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis
- Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024
- Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Karyopharm to Participate at Upcoming Investor Conferences
- Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
- Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024
- Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates
- Karyopharm to Participate at the Jefferies Global Healthcare Conference
- Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference
- Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
